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Dietary Isomalto/Malto-Polysaccharides Increase Fecal Bulk
and Microbial Fermentation in Mice
Rima H. Mistry, Klaudyna Borewicz, Fangjie Gu, Henkjan J. Verkade, Henk A. Schols,
Hauke Smidt, and Uwe J. F. Tietge*
Scope: The prevalence of metabolic-syndrome-related disease has strongly
increased. Nutritional intervention strategies appear attractive, particularly
with novel prebiotics. Isomalto/malto-polysaccharides (IMMPs) represent
promising novel prebiotics that promote proliferation of beneficial bacteria in
vitro. The present study investigates for the first time the in vivo effects of
IMMP in mice.
Methods and results: C57BL/6 wild-type mice received control or
IMMP-containing (10%, w/w) diets for 3 weeks. IMMP leads to significantly
more fecal bulk (+26%, p < 0.05), higher plasma non-esterified fatty acids
(colorimetric assay, +10%, p < 0.05), and lower fecal dihydrocholesterol
excretion (mass spectrometry, −50%, p < 0.05). Plasma and hepatic lipid
levels (colorimetric assays following lipid extraction) are not influenced by
dietary IMMP, as are other parameters of sterol metabolism, including bile
acids (gas chromatography/mass spectrometry). IMMP is mainly fermented
in the cecum and large intestine (high-performance anion exchange
chromatography). Next-generation sequencing demonstrates higher relative
abundance of Bacteroides and butyrate producers (Lachnospiraceae,
Roseburia Odoribacter) in the IMMP group.
Conclusion: The combined results demonstrate that IMMP administration to
mice increases fecal bulk and induces potentially beneficial changes in the
intestinal microbiota. Further studies are required in disease models to
substantiate potential health benefits.
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1. Introduction
Increased consumption of “Western-
style” diets and a sedentary lifestyle
are considered major contributing fac-
tors to the increasing prevalence of the
metabolic syndrome, comprising obe-
sity, insulin resistance, type 2 diabetes,
hypertension, non-alcoholic fatty liver
disease, and cardiovascular disease.[1]
Epidemiological studies have indicated
a relationship between low dietary fiber
intake and risk of developing metabolic
syndrome.[2,3] Whether the epidemiolog-
ically beneficial effects of fiber intake are
a result of lower glycemic index, reduced
energy content or the fact that dietary
fibers stimulate fermentation by gas-
trointestinal (GI) microbiota is currently
not clear. Nevertheless, the American
Heart Association recommends a daily
dietary fiber intake of 25–38 g d−1 (14 g
per 1000 kcal d−1).[4,5] Accumulating
evidence on the potential benefits of di-
etary fibers has generated an increasing
interest in foods that are low in glycemic
index, slowly degraded, or completely
escape digestion.
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Isomalto/malto-polysaccharides (IMMP) are a novel class of
dietary fibers with a prebiotic potential.[6,7] IMMP contain a high
proportion of 𝛼-(1→6) glycosidic linkages. Earlier studies showed
that IMMP can stimulate proliferation and activity of Bifidobac-
terium and Lactobacillus during in vitro fermentation using adult
human fecal inoculum as a microbial source.[7,8] In vitro studies
showed that this modulatory effect on microbial communities
was accompanied by the accumulation of succinate and short-
chain fatty acids (SCFA), in particular acetate and propionate in
the media.[8] These studies, as well as research on similar sub-
strates, such as dextran and isomalto-oligosaccharides (IMOs),
suggest that IMMP may have beneficial effects on metabolism
and health.[9] However, currently no in vivo data are available sup-
porting this assumption. Therefore, we designed the first in vivo
study to investigate the effects of a particular IMMP in a mouse
model. First, we aim to provide a thorough characterization of
the impact of IMMP on the composition of the microbiota in dif-
ferent parts of the intestine. In addition, we chose to investigate
effects of IMMP on (chole)sterol metabolism, which has high
relevance with respect to cardiometabolic disease and integrates
metabolic pathways of host and microbiome. Cholesterol is an
important biomarker of cardiovascular disease.[10] The choles-
terol molecule has a steroid nucleus that cannot be degraded by
mammalian enzymes, hepatocytes can only metabolize choles-
terol into primary bile acids.[11] Intestinal bacteria on the other
hand can synthesize coprostanol and di-hydro-cholesterol out of
cholesterol, poorly absorbable metabolites that promote choles-
terol excretion from the body and thereby result in a deple-
tion of the cholesterol pool.[12] Further, the microbiota can via
bacterial bile salt hydrolase deconjugate primary bile acids and
then further dehydroxylate, oxidize, and epimerize these into sec-
ondary bile acids.[11] Secondary bile acids are more efficiently ex-
creted, thereby also favoring a depletion of the cholesterol pool
as cholesterol is the parent molecule. In addition, bile acids
play an important regulatory role in the control of glucose and
lipid metabolism via signaling through, e.g., the nuclear recep-
tor farnesoid X receptor (FXR) or the G-protein-coupled receptor
TGR5.[11] Characterizing (chole)sterol metabolism therefore can
reveal (patho)physiologically important read-outs that integrate
diet, the metabolic activity of the microbiota and mammalian
metabolic pathways.
2. Materials and Methods
2.1. Animal Experiments
C57BL/6OlaHsd femalemice were obtained fromHarlan (Horst,
the Netherlands). All mice were 9 weeks old at the start of
the dietary intervention. Animals were individually housed in
a light- and temperature-controlled facility (12 h light–dark cy-
cle, 21 °C). All animal experiments were approved by the Com-
mittee of Animal Experimentation at the University of Gronin-
gen (#6905AC) and performed in accordance with the Dutch
National Law onAnimal Experimentation as well as international
guidelines on animal experimentation. IMMP-94 contained 94%
𝛼-(1→6) linkages (Avebe, Veendam, the Netherlands), was made
by enzymatic conversion of potato starch using the GTFB 4,6-𝛼-
glucanotransferase enzyme purified from E.coli and pullulanase
(PromozymeD2, Novozymes, Bagsvaerd, Denmark) as described
previously[7] and kindly supplied by Dr. Hans Leemhuis (Avebe).
Animals were fed ad libitum with either control (n = 6) or IMMP
(10% w/w, n = 6) supplemented diet for 21 days. Control base-
line diet (Safe Diets, Augy, France) contained 60.94% corn starch,
0.06% cholesterol, 20% caseinate, 0.3% l-cystine, 7% carbohy-
drate mix (sucrose:maltodextrin, 50:50), 7% soya bean oil, 0.2%
choline bitartrate, 3.5% mineral mixture, and 1% vitamin mix-
ture (w/w). A modified diet containing 10% IMMP was obtained
by replacing an equal amount of corn starch (50.94% corn starch,
0.06% cholesterol, 20% caseinate, 0.3% l-cystine, 7% carbohy-
drate mix, 7% soya bean oil, 0.2% choline bitartrate, 3.5% min-
eral mixture, and 1% vitamin mixture).
Fecal samples were freshly collected from the animals at time
points 0, 24, 48 h, 3, 7, 14, and 21 days and stored at −80 °C un-
til further analysis. Animals were weighed weekly. Food intake
and fecal output were recorded on days 7, 14, and 21. At day
21, the gallbladder was cannulated under anesthesia (hypnorm
1 mg kg−1 body weight; diazepam 10 mg kg−1 body weight). Bile
was collected continuously for 20 min and the rate of secretion
was determined gravimetrically.[13] After termination, theGI tract
was excised and the entire contents of stomach, small intestine,
cecum, and large intestine were individually collected and imme-
diately stored at −80 °C for later analysis.
2.2. Analysis of Bile, Plasma, and Liver
At the time of termination, a large blood sample was collected
by heart puncture. Plasma was isolated and aliquots were stored
at −80 °C until further analysis. Liver was excised at termina-
tion and homogenized. Extraction of lipids was performed from
the homogenates using the Bligh and Dyer procedure and re-
dissolved in water containing 2% Triton X-100.[13] Liver as well
as plasma total cholesterol and triglycerides were measured us-
ing commercially available reagents (Roche, Diagnostic, Basel,
Switzerland). Biliary bile acid and cholesterol concentrations
were analyzed as described earlier.[14]
2.3. Fecal Sterol and Bile Acid Measurements
Feces were collected over a period of 24 h. Fecal samples were
dried, weighed, and ground. A total of 50 mg of feces were
used to extract neutral sterols and bile acids that were mea-
sured using gas–liquid chromatography as published.[15] Plasma
bile acids were methylated with a mixture of acetyl chloride
and trimethylsilylated with pyridine, N, O-Bis (trimethylysi-
lyl) trifluoroacetamide, and trimethylchlorosilane. Plasma bile
acids were then determined using liquid chromatography–mass
spectrometry.[15]
2.4. DNA Extraction from Intestinal Content and Microbiota
Analysis Using Next Generation Sequencing
Approximately 0.1 g of intestinal content sample were used
for DNA extraction. Total bacterial DNA was extracted
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according to a previously described protocol with minor
modifications.[8] Intestinal content samples were homoge-
nized in 350 µL STAR buffer, with cooling at room temper-
ature and the bead-beating step was repeated using 200 µL
of fresh STAR buffer. The V4 region of 16S ribosomal RNA
(rRNA) genes was amplified using uniquely barcoded primers
515F-n (5’-GTGCCAGCMGCCGCGGTAA-) and 806R-n (5’-
GGACTACHVGGGTWTCTAAT) (200 × 10−9 m each).[16]
Purified PCR products were pooled into libraries and sent
for adapter ligation and HiSeq sequencing (GATC-Biotech,
Konstanz, Germany). Data processing and analysis was carried
out using NG-Tax.[16] In brief, libraries were filtered to contain
only read pairs with perfectly matching barcodes that were
subsequently used to separate reads by sample. Operational
taxonomic units (OTUs) were assigned using an open reference
approach and the SILVA_111_SSU 16S rRNA gene reference
database (https://www.arb-silva.de/).[17]
2.5. Analysis of Fecal Short-Chain Fatty Acids
Feces were kept frozen before being processed for SCFA anal-
ysis. Approximately 50 mg of feces were mixed with 0.35 mL
of 50 mmol L−1 sulfuric acid and 0.025 mL of 4 mg mL−1 2-
ethylbutyric acid. The mixture was homogeneously suspended
by vortex mixing in the presence of glass beads (rinsed with Mil-
lipore water beforehand) in an Eppendorf tube. Subsequently the
samples were centrifuged for 20 min at 18 600 × g and 4 °C,
and the supernatant was analyzed by the high performance liq-
uid chromatography–refractive index (HPLC–RI) method pub-
lished previously.[18] The dry matter content of mouse feces was
estimated by comparing the weight differences before and after
freeze drying the feces.
2.6. Analysis of Oligosaccharide Profiles of Murine Digesta by
HPAEC-PAD
The digesta samples from stomach, small intestine, cecum, and
large intestine of six mice each from the control and the IMMP
diet groups were freeze dried and then mixed in Millipore wa-
ter at a concentration of 2.5 mg mL−1. After mixing thoroughly
by vortex, the tube containing the suspension was put in boiling
water for 5min and then centrifuged at 18 600× g for 20min. The
supernatant was taken and analyzed by high performance an-
ion exchange chromatography–pulsed amperometric detection
(HPAEC–PAD). Ten microliters of sample was injected into a
Dionex ICS 5000 system (Dionex) with a CarboPac PA-1 column
(250 mm × 2 mm inner diameter (ID)) and a CarboPac PA guard
column (25 mm × 2 mm ID). The temperature of the column
was set at 20 °C. The flow rate of the two mobile phases (A)
0.1 m NaOH and (B) 1 m NaOAc in 0.1 m NaOH was set to
0.3 mL min−1. The gradient elution was applied as follows: 0–
40 min, 0–40% B; 40–40.1 min, 40–100% B; 40.1–45 min, 100%
B; 45–45.1 min, 100–0% B; 45.1–60 min, 0% B. PAD (Dionex
ISC-5000 ED) was used to monitor elution. HPAEC data were
processed using ChromeleonTM 7.1 software (Dionex). Glucose,
isomaltose, and maltodextrin standards, as well as an IMMP di-
gest treated with pure dextranase from C. Erraticum, were pre-
pared and included in the HPAEC analysis, to identify oligosac-
charide peaks as detailed previously.[8]
2.7. Statistics
Statistical analysis onmetabolic parametersmeasured in plasma,
liver, and feces was performed using GraphPad Prism soft-
ware (San Diego, CA). All data are presented as mean ± SEM.
Statistical differences between groups were assessed using the
Mann–Whitney U-test. Statistical significance for all compar-
isons was assigned at p < 0.05. Microbial composition data were
expressed as a relative abundance of each genus level taxon ob-
tained with NG-Tax. A 5000 reads per sample rarefraction cut-off
was used in alpha diversity indices (Shannon, Chao1, and PD
Whole Tree). Calculations and group comparisons were done us-
ing nonparametric two-sample t-tests with Monte Carlo permu-
tations in QIIME.[19] The association between microbiota com-
position and the dietary treatment group was investigated with
RDA analysis in Canoco5, with significance assessed using a per-
mutation test.[20] Beta diversity analysis, including weighted and
unweighted unifrac distances estimates, and ANOSIM group
comparisons were calculated in QIIME using rarefied data.
Genus level taxa that differed significantly between different
treatment groups were identified with Kruskal–Wallis analysis
using QIIME.[19,21]
3. Results
3.1. IMMP Utilization along the GI Tract
The digesta from different parts of the GI tract of mice fed dur-
ing a period up to 21 days with either control or IMMP con-
taining diet were analyzed by HPAEC–PAD, in order to moni-
tor the degradation of these fiber polymers from the diets and
the formation of oligosaccharides. The figure depicts represen-
tative changes reproducibly observed in each individual animal
investigated. 𝛼-1-4-linked maltodextrin peaks were present in the
stomach and small intestine digesta of animals from both di-
etary treatment groups (Figure 1). Thesemaltodextrin peaks were
products of starch digestion by murine digestive enzymes. Dif-
ferences were also noticed in the small intestine between the two
groups of mice: the isomaltose peak (elution at ≈6 min) and a
broad peak (17–24 min) were only present in the mice receiv-
ing IMMP supplemented diets. The broad peak corresponded
to the unseparated IMMP polymer fraction, whereas the isoma-
ltose peak indicated ongoing microbial fermentation at a very
low level. When comparing the digesta of cecum and large intes-
tine between the two groups, a series of separated 𝛼-1-6-linked
isomalto-oligosaccharide peaks were clearly seen in the IMMP
mice, whereas hardly any carbohydrate peak was detected in di-
gesta of control mice. The observation that there were no sub-
stantial differences between cecum and large intestine suggests
that themajor IMMP degradation by bacterial dextranases occurs
in the cecum. Looking to individual peak heights, a slight further
degradation of the broad peak at 17–24 min and an almost equal
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Figure 1. High performance anion exchange chromatography (HPAEC) elution patterns of digesta from mice fed with A) control and B) IMMP supple-
mented diets. The digesta are taken from different parts of the gastrointestinal tract: a) stomach, b) small intestine, c) cecum, and d) large intestine.
IMMP peaks (2–11) in a box and maltodextrin peaks (①–⑥) are annotated, with the number indicating the degree of polymerization (DP).
level of oligosaccharides present points to an enduring utilization
of the IMMP structures. Please note that the glucose contents in
these profiles are difficult to be quantitatively compared, since
released glucose is rapidly utilized. Some remaining isomalto-
oligosaccharides were still present in the fecal samples (result not
shown). The release of the isomalto-oligosaccharides indicated
the degradation of the polysaccharides during microbial fermen-
tation of IMMP, and this fermentation took mainly place in the
cecum and large intestine, although low level fermentation activ-
ity was also already detected in the small intestine.
3.2. Changes in GI Microbiota Composition
The total number of sequencing reads obtained for the 60 sam-
ples was 11 440 993 (min = 1643, max = 564 991, median =
173 066.5, mean = 190 683.2, SD = 130 379.2). Samples were
rarefied at 5000 reads per sample depth prior to alpha diversity
analyses. Alpha diversity estimates included Shannon diversity,
Chao1, and PD Whole Tree; however, no significant differences
were detected in any of the measures between control and treat-
ment groups (Figure S1, Supporting Information).
The RDA analysis of fecal microbiota on day 2 showed that
diet could explain 10.6% of the variation in the relative abun-
dance of genus level taxa, however, the difference between the
control and IMMP groups was not significant (FDR = 0.252,
data not shown). At day 21, contents from different parts of the
murine GI tract were used for detailed microbiota analyses. In
small intestine digesta, diet explained 12.1% of the microbiota
variation, but the difference was not statistically significant
(FDR = 0.208, Figure 2A). In cecum, however, diet explained
20.3% of the variation and this effect was significant (FDR =
0.014, Figure 2B). Finally, diet significantly explained 16.8% of
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Figure 2. Constrained analysis (RDA) in the control and IMMP supplemented diet groups and their association with the genus level microbiota profiles
in different parts of the gastrointestinal tract. The samples were collected from A) small intestine, B) cecum, and C) large intestine. Samples are labeled
and enveloped based on their assignment to different treatment groups. Genus-level taxa that significantly differed in their relative abundance between
control and IMMP supplemented diet groups in D) small intestine, E) cecum, and F) large intestine. When the taxonomic assignment could not be
made at genus level, the lowest classifiable taxonomy assignment is used instead, and unidentified genus is indicated with “g_g.”
the microbiota variation at genus level classification in large
intestine samples (FDR = 0.04, Figure 2C).
In the small intestine, 22 genus level taxa were detected in
the IMMP group, and additional 19 taxa were found in the con-
trol group. The 19 taxa had low relative abundance and together
contributed to 1.7% of the total bacteria detected in the small in-
testine of the control animals. ANOSIM analysis showed no sig-
nificant difference between treatment groups when weighted or
unweighted unifrac distances were used (p = 0.47 and p = 0.11,
respectively). Kruskal–Wallis analysis showed no statistically sig-
nificant differences in the relative abundance of genus level taxa
between the two treatment groups (FDR adjusted p > 0.05).
When unadjusted p-values were used a just significant result was
detected for Peptostreptococcaceae_Incertae_Sedis (p = 0.049),
which was 114 times more abundant in the IMMP group com-
pared to the control (Figure 2D). In addition, animals receiving
IMMP diet had on average an 11 times lower relative abundance
of genus Enterococcus, 19 times lower Akkermansia, 24 times
lower Bacteroides, and 50 times less Turicibacter compared to the
control group (Table S1, Supporting Information). Overall, these
four taxa accounted for a cumulative relative abundance of 15.7%
in the control group, and only 0.7% in the IMMP group. There
were no differences in the average relative abundance of Bifi-
dobacterium and Lactobacillus between the IMMP and the control
group.
In cecum, 37 genus level groups were detected with four
groups found only in the IMMP-fed animals and four other taxa
detected only in the control group. ANOSIM analysis showed sig-
nificant differences between treatment groups when weighted
or unweighted unifrac distances were used (p = 0.01, for both).
Kruskal–Wallis analysis showed no statistically significant dif-
ferences between relative abundances of individual genus level
taxa between the two treatment groups (FDR > 0.05, Figure 2E),
but based on unadjusted p-values, we identified differences in
the relative abundance of genera Alistipes, Prevotella, Roseburia,
Pseudobutyrivibrio, Parabacteroides, and Incertae Sedis in families
Peptostreptococcaceae, Ruminococcaceae, and Lachnospiraceae
(each p < 0.05). Compared to the control group, the IMMP group
had a fivefold higher average relative abundance for Roseburia,
and a 26-fold lower relative abundance of Prevotella, 13-fold lower
Akkermansia, and ninefold lower Alistipes and Parabacteroides. In
addition, the IMMP treated animals had on average a twofold
lower relative abundance of Bifidobacterium, and threefold higher
relative abundance of Lactobacillus as compared to the control
group, however, these differences were not statistically signifi-
cant (Table S1, Supporting Information).
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In the large intestinal samples, 40 genus level taxa were de-
tected, of which four were only found in the control animals
and eight were only found in the IMMP group. ANOSIM anal-
ysis showed no significant difference between treatment groups
when weighted unifrac distances were used (p = 0.1), however,
the difference was significant when unweighted distances were
compared (p = 0.01). Kruskal–Wallis analysis showed no statis-
tically significant differences between the two treatment groups
(FDR > 0.05, Figure 2F), however unadjusted p-values indicated
differences in the relative abundance of Odoribacter, Parabac-
teroides, Prevotella, Alistipes, family Peptostreptococcaceae genus
Incertae Sedis, and uncultured genus within the order Clostridi-
ales. Compared to the control group, the IMMP animals showed
a 11-fold lower relative abundance of Parabacteroides and Turi-
cibacter, eightfold lower Akkermansia, a sevenfold lower level of
unidentified genus within the order Bacteroidales, and a fivefold
higher relative abundance ofOdoribacter.The IMMPanimals also
had on average a two times lower relative abundance of Bifidobac-
terium, and a three times higher relative abundance of Lactobacil-
lus, however, these differences were not statistically significant (p
= 0.87 for both taxa).
3.3. SCFA Production in IMMP-Fed Mice
SCFA are among the major products of bacterial fermentation.
Our analyses of SCFA and other acids in feces showed that aver-
age succinic and lactic acid production increased in both groups
at day 2 and 3, and decreased thereafter, except on day 14 when
an increase in lactic acid (p < 0.05) in feces from the IMMP
groupwas noted (Figure 3A,B). Propionic acid concentrations de-
creased throughout the duration of the study, while the levels of
butyric and acetic acid remained stable (Figure 3C–E). A signifi-
cantly lower level of propionic acidwas seen in IMMP fedmice on
day 21 (p< 0.05) and a lower level of lactic acid on day 2 (p< 0.05).
However, overall, no consistent differences in these parameters
were observed, especially no substantial increase in fecal SCFA,
lactic, and succinic acid levels in response to IMMP.
3.4. Metabolic and Physiological Responses to IMMP
To study the potential physiological effects of the IMMP-derived
SCFA, we investigated the impact of the different diets on lipid
metabolism (Table 1). First, body weight and food intake in both
groups remained stable throughout the dietary intervention pe-
riod (Table 1). Plasma non-esterified fatty acids (NEFA) were
higher (+8%, p < 0.05) in IMMP-fed mice compared with con-
trols. Liver weight was unaffected and also liver cholesterol and
triglyceride contents remained unchanged in either group. Also,
the biliary excretion of bile acids and cholesterol did not change
upon IMMP feeding. At the end of the dietary intervention, the
IMMP-supplemented group had a significantly higher fecal bulk
mass (+35%, p < 0.05) and lower levels of fecal dihydrocholes-
terol (−50%, p < 0.05), a product of bacterial metabolism. Fecal
total neutral sterol and bile acid excretion remained unchanged.
In terms of bile acid species in feces, control and IMMP-fedmice
had a similar composition (Figure 4). Throughout the duration
of the experiment the fecal water content did not vary between
the treatment groups, except on days 3 and 14, when it was sig-
nificantly (p < 0.05) higher in the control group (d = 3: control
= 14.0 ± 2.6%; IMMP = 10.5 ± 3.3% and d = 14: control =
20.9 ± 10.2%; IMMP = 10.2 ± 2.7%).
4. Discussion
This study is to the best of our knowledge the first to investigate in
vivo properties and related physiological effects of IMMP supple-
mentation in amurinemodel. Our data demonstrate that inmice
fed IMMP-supplemented diet, the fermentation of IMMP oc-
curred mostly in the cecum and large intestine and only at a very
low level in the small intestine. This observation is in line with
the changes observed in the microbiota composition in these re-
gions of the GI tract. Beta diversity analysis with both weighted
and unweighted unifrac distances, as well as genus level relative
abundance based RDA analysis all showed that IMMP supple-
mentation had a significant effect on microbiota composition in
cecum and large intestine, but not in the ileum. In the large in-
testine, however, the significant effect was not detected when us-
ing weighted unifrac distances, suggesting that the significance
was mostly due to changes in the composition of low abundance
taxa.[22] In cecum, IMMP diet resulted in significantly higher lev-
els of Lachnospiraceae Incertae Sedis (p < 0.05), and, although
not statistically significant, increases in a highly abundant re-
lated genus within the Lachnospiraceae family (unidentified) and
in Bacteroides. The increase in Bacteroides was also observed in
the large intestine and this finding was in line with an earlier
in vitro study showing that IMMP fermentation can be linked
with an increase in both, the relative abundance and activity of
Bacteroides.[8] An increased abundance of Bacteroides is largely
regarded as a beneficial effect, based on data demonstrating a
strong association between decreased Bacteroides and obesity as
well as metabolic disease.[23] In the cecum, IMMP was further
associated with a significant increase in Roseburia, and in both,
cecum and large intestine, we detected a higher relative abun-
dance of Odoribacter. Lachnospiraceae, and Roseburia are known
to be saccharolytic groups associated with high fiber diets, while
Odoribacter is largely asaccharolytic.[24,25] Lachnospiraceae, Rose-
buria, and Odoribacter are important producers of butyrate. Bu-
tyrate is a relevant metabolite produced by the gut microbiota
that has been implicated in improving metabolic control, as well
as having inhibiting effects on cancer cell growth, largely via in-
hibition of histone deacetylases (HDAC).[26,27] Further, butyrate
upregulates the expression of endogenous host defense peptides
in the gut and increases energy expenditure by activating brown
adipose tissue.[28,29] Fecal analysis, though, did not reveal a signif-
icant increase in butyrate excretion in IMMP-fed mice, a finding
likely attributable to the highly efficient uptake of this SCFA into
colonocytes.[30,31]
In stomach and small intestine, we observed 𝛼-1-4-linked mal-
todextrins that were the main products of starch digestion by
murine digestive enzymes. This was in line with previous in vitro
studies in which small intestine extracts from rats were incu-
bated with IMMP.[7] Given that IMMP represents a novel class
of dietary fiber, it is essential to identify groups of bacteria that
are promoted by dietary IMMP in vivo. Our study is the first
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Figure 3. Short-chain fatty acid profiles in murine feces from day 0 to day 21. In fecal samples, A) lactic acid, B) succinic acid, C) acetic acid, D) propionic
acid, and E) butyric acid were measured. Solid line, control group; dashed line, IMMP group. *p < 0.05.
to use next generation sequencing of PCR-amplified 16S rRNA
genes to systematically and comprehensively explore the relative
abundance of various groups of bacteria in different parts of the
intestine of IMMP-fed mice. Previous in vitro studies with hu-
man fecal inoculum incubated with IMMP have shown increases
in Bifidobacterium and Lactobacillus.[7,8] These strains are consid-
ered probiotic microorganisms as they confer health benefits on
the host via generation of key metabolites such as SCFA. How-
ever, in the current study it appeared that while the relative abun-
dance of Lactobacillus increased upon IMMP feeding, bifidobac-
teria were relatively reduced in their relative abundance, although
it should be noted that none of these changes in the relative abun-
dances were statistically significant. Interpreting these findings,
one needs to take into account that the murine gut ecosystem
is different from that of the human GI tract. Therefore, further
human studies seem warranted to corroborate these results.
Mammals lack digestive enzymes for degrading dietary fibers.
In rodents, even though certain microbial communities are
present in stomach and small intestine, large intestine and, im-
portantly, cecum are the most active fermentation sites.[32] Thus,
most dietary fibers pass through the upper gastrointestinal tract
and are fermented in cecum and large intestine. Fermentation
results in generation of multiple groups of metabolites such as
intermediate acids as lactic and succinic acid and final metabo-
lites as SCFA. SCFA can regulate several pathways related to lipid
and glucose metabolism.[33–35] The present study followed the
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Table 1. Animal characteristics, plasma, liver, and fecal parameters of lipid
metabolism inmice fed control or IMMPdiets. Values are shown asmeans
per group ± SDs.
Control Diet IMMP Diet
Animal characteristics
Body weight (d = 0) 19.48 ± 1.38 20.28 ± 0.66
Body weight at termination (d = 21) 19.93 ± 1.07 20.15 ± 1.00
Food intake [g d−1] 3.18 ± 0.22 3.26 ± 0.21
Plasma
Cholesterol [mmol L−1] 2.32 ± 0.67 2.47 ± 0.17
Triglycerides [mmol L−1] 0.31 ± 0.16 0.36 ± 0.14
NEFA
c)
[mmol L−1] 1.01 ± 0.05 1.10 ± 0.03a)
Total plasma bile acids, µmol·L−1 3.05 ± 1.25 5.49 ± 3.23
Liver
Liver weight (d = 21)
-absolute [g] 0.80 ± 0.11 0.87 ± 0.07
-relative [% of body wt] 4.02 ± 0.47 4.32 ± 0.44
Triglycerides [nmol mg−1 liver] 21.31 ± 4.24 20.26 ± 7.23
Cholesterol [nmol mg−1 liver] 10.24 ± 3.31 9.30 ± 1.30
Bile flow [µL min−1 100 g body wt−1] 9.17 ± 2.21 9.34 ± 2.31
Biliary BA secretion [µmol d−1 100 g body wt−1] 34.06 ± 9.75 40.04 ± 5.46
Feces
Feces (dry) [mg d−1 1 g body wt−1] 5.94 ± 0.49 8.05 ± 1.03a)
Fecal Coprostanol [µmol d−1] 0.95 ± 0.46 0.76 ± 0.58
Fecal Cholesterol [µmol d−1] 1.55 ± 0.13 1.65 ± 0.34
Fecal DiH-Chol
b)
[µmol d−1] 0.23 ± 0.03 0.18 ± 0.03a)
Total fecal neutral sterols [µmol d−1] 2.72 ± 1.69 2.60 ± 0.45
Total fecal bile acids [µmol d−1] 2.67 ± 0.53 1.17 ± 1.40
a)p < 0.05; b)DiH-Chol, dihydrocholesterol; c)NEFA, nonesterified fatty acids.
Figure 4. Bile acid composition in feces of control and IMMP-fed mice. At
day 21, fecal samples were collected and processed for bile acid analysis as
detailed inmethods. Abbreviations: MCA,muricholic acid; CA, cholic acid;
CDCA, chenodeoxy-cholic acid; DCA, deoxycholic acid; UDCA, ursodeoxy-
cholic acid.
production of specific SCFA over several time periods. Subtle dif-
ferences between both groups were observed for most SCFA and
their precursors, such as lactic and succinic acids. At the end of
the dietary intervention significantly lower propionic acid con-
centrations were detected in IMMP-fed animals. Propionic acid
has been shown to attenuate lipid biosynthesis in the liver.[36,37]
However, the unchanged hepatic lipid content observed in our
study argues against a physiological significance of this result.
On the other hand, lactic acid that is normally produced endoge-
nously in high concentrations upon exercise in host muscles but
only in low concentration in the intestine, is an intermediate of
bacterial fermentation and can be used by some bacteria, together
with acetic acid, to synthesize butyric acid. In adipose tissue, lac-
tic acid has been shown to have a signaling function, being a nat-
ural ligand for GPR81 thereby inhibiting lipolysis.[38] At the end
of the dietary intervention, higher lactic acid levels were detected
in IMMP-fed mice compared to the control group. However, it
is also important to point out that an increase in luminal SCFA
does not always reflect uptake of SCFA by the host and the subse-
quent induction of metabolic effects.[39] Thus, it is possible that
the uptake of SCFA is different in both groups that needs to be
further investigated, ideally using animal models with the capac-
ity to resemble human metabolic disease states.
Cholesterol homeostasis is maintained by a balance between
cholesterol intake, cholesterol synthesis in the host, absorption of
cholesterol in the intestine, and the removal of cholesterol via the
feces. Cholesterol is also a key biomarker of cardiovascular dis-
ease. Gut bacteria can reduce cholesterol to its derivatives, such
as dihydrocholesterol and coprostanol, which are not absorbed by
the host, but largely excreted into the feces. In the present study a
small but significant decrease in fecal dihydrocholesterol output
was noted after feeding the IMMP diet. However, since dihydro-
cholesterol represents only a minor fraction of total fecal neutral
sterol output, overall fecal neutral sterol excretion upon IMMP
administration remained unaltered. The intestinal microbiota
also plays an important role in modulating bile acids and thereby
subsequently cholesterol turnover.[40] However, the present study
shows that IMMP-fed mice have no substantial alterations in the
respective composition of plasma, biliary, and fecal bile acids. Fe-
cal bile acid profiles integrate endogenous synthesis and modifi-
cations by bacterial enzymes suggesting that based on our results
no major effects either in the host or in microbial communities
involved in bile acid metabolism are discernible.
A significant increase was seen in the total fecal output of
IMMP fedmice, indicating improved fecal bulk in these animals.
Bulk in the large intestine is associated with several beneficial
effects such as stimulating defecation, diluting toxins, and dis-
tributing intracolonic pressure, while lower fecal weight is associ-
ated with constipation and colorectal cancer.[41–44] Since the total
fecal neutral sterol and bile acid excretion remained comparable
between the control and the IMMP fed groups, we believe that the
changes in fecal bulk have no major impact on the (chole-)sterol
balance. The overall weak metabolic response to IMMP supple-
mentation might be explained by the fact that this dietary fiber is
designed to function in the lower parts of the GI tract where it can
be fermented by the microbiota. In mice, cecum and large intes-
tine are themain fermentation sites, while the proximal intestine
is metabolically more active.
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In summary, IMMP supplementation increased fecal bulk
and microbial fermentation in the intestine resulting in poten-
tially beneficial alterations inmicrobiota composition without ad-
versely impacting host metabolism. Subsequently, studies in dis-
ease models and humans are needed to investigate whether the
intriguing changes observed here translate into actual health ben-
efits.
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